Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.
Mark J RoschewskiManish R PatelPatrick M ReaganNakhle S SabaGraham P CollinsHendrick-Tobias ArkenauSven de VosBarret R B NuttallMelih AcarKathleen BurkeRafael D WhiteMaria UdristeShringi SharmaBrian DoughertyDaniel StetsonDavid F JenkinsAndrew MortlockAlessandra ForcinaVeerendra MunugalavadlaIan W FlinnPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Targeting both STAT3 and BTK in combination is safe and tolerable but efficacy is limited in R/R DLBCL. Results support evaluation of circulating tumor DNA as a biomarker for clinical response.